ATE92107T1 - N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. - Google Patents

N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.

Info

Publication number
ATE92107T1
ATE92107T1 AT90304575T AT90304575T ATE92107T1 AT E92107 T1 ATE92107 T1 AT E92107T1 AT 90304575 T AT90304575 T AT 90304575T AT 90304575 T AT90304575 T AT 90304575T AT E92107 T1 ATE92107 T1 AT E92107T1
Authority
AT
Austria
Prior art keywords
fusion proteins
serum albumin
human serum
terminal fragments
containing fusion
Prior art date
Application number
AT90304575T
Other languages
English (en)
Inventor
David James Ballance
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Application granted granted Critical
Publication of ATE92107T1 publication Critical patent/ATE92107T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT90304575T 1989-04-29 1989-04-26 N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. ATE92107T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898909919A GB8909919D0 (en) 1989-04-29 1989-04-29 Small polypeptides
EP90304575A EP0399666B1 (de) 1989-04-29 1990-04-26 N-terminale Fragmente von menschliches Serumalbumin enthaltenden Fusionsproteinen

Publications (1)

Publication Number Publication Date
ATE92107T1 true ATE92107T1 (de) 1993-08-15

Family

ID=10656003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90304575T ATE92107T1 (de) 1989-04-29 1989-04-26 N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.

Country Status (7)

Country Link
EP (2) EP0407008A3 (de)
AT (1) ATE92107T1 (de)
DE (1) DE69002395T2 (de)
DK (1) DK0399666T3 (de)
ES (1) ES2060033T3 (de)
GB (1) GB8909919D0 (de)
WO (1) WO1990013306A2 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE69012950T2 (de) * 1989-10-13 1995-03-16 Takara Shuzo Co Antikrebsmittel.
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2719593B1 (fr) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
JP3192067B2 (ja) * 1995-10-09 2001-07-23 科学技術振興事業団 ペプチドとコラーゲン収縮阻害剤
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US20040010134A1 (en) 2000-04-12 2004-01-15 Rosen Craig A. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP1322667A4 (de) * 2000-08-25 2004-08-18 Human Genome Sciences Inc Tumor-nekrose-faktor rezeptoren 6-alpha und 6-beta
SI1355942T1 (sl) 2000-12-07 2009-02-28 Lilly Co Eli Glp-1 fuzijski proteini
DK1463751T3 (da) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albuminfusionsproteiner.
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
RU2401842C2 (ru) 2004-10-08 2010-10-20 Домантис Лимитед Антагонисты и способы их применения
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
EP3058972A1 (de) 2005-11-17 2016-08-24 Zogenix, Inc. Abgabe von viskosen formulierungen durch nadellose injektion
EP1816201A1 (de) 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
NZ580686A (en) 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
ES2563061T3 (es) 2008-04-28 2016-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
BRPI0913007A2 (pt) 2008-05-02 2019-09-24 Novartis Ag moléculas de ligação aprimoradas à base de fibronectina e usos das mesmas
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
BRPI0921586A2 (pt) 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc articuladores de albumina de soro humana e conjugados destes
CN102307897B (zh) 2008-12-05 2016-01-20 葛兰素集团有限公司 选出蛋白酶抗性多肽的方法
EA022925B1 (ru) 2009-02-19 2016-03-31 Глаксо Груп Лимитед Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
WO2010138555A2 (en) 2009-05-26 2010-12-02 University Of Florida Research Foundation, Inc. Small peptide expression system in mammalian cells
WO2011006914A2 (en) 2009-07-16 2011-01-20 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
PE20121564A1 (es) 2009-10-27 2012-11-29 Glaxo Group Ltd Polipeptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
EP2805965A1 (de) 2009-12-21 2014-11-26 Ambrx, Inc. Modifizierte Schweine-Somatotropin-Polypeptide und deren Verwendungen
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
ES2659406T3 (es) 2010-05-06 2018-03-15 Novartis Ag Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
MX356527B (es) 2010-07-09 2018-06-01 Bioverativ Therapeutics Inc Polipeptidos de factor ix y metodos para usarlos.
PL2605789T3 (pl) 2010-08-17 2019-11-29 Ambrx Inc Zmodyfikowane polipeptydy relaksyny i ich zastosowania
JP6057896B2 (ja) 2010-08-20 2017-01-11 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
EP2643353A1 (de) 2010-11-24 2013-10-02 Novartis AG Multispezifische moleküle
EP2726502A1 (de) 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin-fusionspolypeptide und ihre verwendung
AU2012283235A1 (en) 2011-07-08 2014-01-09 Bayer Intellectual Property Gmbh Fusion proteins releasing Relaxin and uses thereof
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
WO2013084148A2 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
CN107739409A (zh) 2012-05-18 2018-02-27 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
WO2014164703A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
EP2970479B1 (de) 2013-03-14 2019-04-24 Novartis AG Antikörper gegen notch 3
WO2015073918A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
CN112043835B (zh) 2013-12-06 2022-10-21 韩捷 用于含氮和羟基的药物的生物可逆引入基团
CN106232800B (zh) 2014-03-25 2020-07-03 泰尔茂比司特公司 介质的被动替代
EP3157947A1 (de) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15-fusionspolypeptid und verwendung davon
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
JP6995627B2 (ja) 2015-05-19 2022-02-04 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017109706A1 (en) 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3851457A1 (de) 2016-01-21 2021-07-21 Novartis AG Gegen cll-1 gerichtete multispezifische moleküle
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
CN110612344B (zh) 2017-03-31 2023-09-12 泰尔茂比司特公司 细胞扩增
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CA3098420A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
US20220025344A1 (en) 2018-11-26 2022-01-27 Novartis Ag Lpl-gpihbp1 fusion polypeptides
EP3914282A1 (de) 2019-01-25 2021-12-01 Ospedale San Raffaele S.r.l. Inhibitor von dux4 und verwendungen davon
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
EP3972993A1 (de) 2019-05-21 2022-03-30 Novartis AG Variante cd58-domänen und deren verwendungen
CR20220096A (es) 2019-09-06 2022-05-11 Novartis Ag Proteínas de fusión terapéuticas
EP4240491A1 (de) 2020-11-06 2023-09-13 Novartis AG Cd19-bindende moleküle und verwendungen davon
TW202400658A (zh) 2022-04-26 2024-01-01 瑞士商諾華公司 靶向ｉｌ—１３和ｉｌ—１８的多特異性抗體

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) * 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
SE459586B (sv) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
AU2719088A (en) * 1987-11-09 1989-06-01 Chiron Ophthalmics Inc. Wound healing composition and method

Also Published As

Publication number Publication date
EP0407008A2 (de) 1991-01-09
EP0399666B1 (de) 1993-07-28
GB8909919D0 (en) 1989-06-14
EP0407008A3 (en) 1991-07-17
DK0399666T3 (da) 1993-08-30
WO1990013306A3 (en) 1991-05-02
DE69002395D1 (de) 1993-09-02
EP0399666A1 (de) 1990-11-28
DE69002395T2 (de) 1993-11-25
WO1990013306A2 (en) 1990-11-15
ES2060033T3 (es) 1994-11-16

Similar Documents

Publication Publication Date Title
DE69002395T2 (de) N-terminale Fragmente von menschliches Serumalbumin enthaltenden Fusionsproteinen.
ATE309360T1 (de) Vaskularer endothelialer wachstumsfaktor 2
DE69634726D1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
DE3874798D1 (de) Therapeutisches proteinagens in form von aerosol.
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
HUT54213A (en) Process for the enzymatic removal of n-terminal sequence of proteins
ATE171216T1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
AU676859B2 (en) Synthetic peptides, antibodies against them and their use
DE3686295D1 (de) Reinigung von koagulationsfaktoren des blutes und von anderen proteinen auf sulfatierten nicht carbohydratierten matrizen.
ATE304371T1 (de) Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
ES2155437T3 (es) Cola mejorada para tejidos preparada a partir de un crioprecipitado.
DE69432608D1 (de) Expression von inhibitoren vom plasminogenaktivator vom urokinasetyp
ATE111484T1 (de) Verbindungen zur verhinderung von thrombose.
DE69010750T2 (de) Antikörper gegen Fibrin, immunogene Peptide für die Herstellung dieser Antikörper, Verfahren zur Bestimmung von Fibrin und pharmazeutische Zubereitungen auf der Basis dieser Antikörper.
ATE205529T1 (de) Reninaktive substanz enthaltend humanes prorenin und antikörper gegen das prorenin profragment
ES2101694T3 (es) Expresion de edulcorantes proteinicos en levadura.
MY107451A (en) Cloning and expression of a rhoptry associated protein of p.falciparum
EP0326013A3 (de) Von menschlichem alpha-2-Plasmin-Inhibitor abgeleitete neue Proteine oder Proteine, die diesen ähnlich sind
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
DE69002383T2 (de) Zusammensetzung zur Heilung von Autoimmunkrankheiten.
DE3888078T2 (de) Veränderungsverfahren für Peptide und Proteine.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
EELA Cancelled due to lapse of time